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ABSTRACT 
Background Migraine is a prevalent disorder characterized by recurrent headache attacks preceded or 
accompanied by aura in a subgroup of patients. Migraine often occurs together with major depressive 
disorder (MDD). Alterations of adipokine levels have been reported both in migraine and MDD. In 
this cross-sectional study we aimed to assess the associations between serum leptin and adiponectin 
levels and migraine or migraine subtypes. Analyses were adjusted for a lifetime history of MDD in 
order to investigate the association between adipokines and migraine under consideration of 
depression status. 
Methods We included 3,025 participants from the CoLaus/PsyCoLaus study. The impact of leptin 
and adiponectin levels on diagnosis of migraine was analyzed by binary regression analyses, adjusting 
for variables known to influence adipokine levels. Subgroup analyses were conducted based on the 
presence of aura.  
Results Crude leptin levels were significantly higher in subjects with migraine than controls (Mann-
Whitney U = 515,102, p = 6E-07). When performing adjusted analyses, leptin levels were found to be 
significantly higher in subjects with migraine (OR = 1.22, p = 0.024) and migraine with aura (OR = 
1.34 p = 0.004).  
Discussion High leptin levels might play a role in the pathogenesis of migraine and migraine with 
aura. 
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INTRODUCTION 
Migraine is a disabling primary headache disorder of neurovascular origin that is three times more 
frequent in women (1), with a prevalence of 1 billion of people worldwide (2). Ranked as the third 
most prevalent disorder and seventh-highest speciﬁc cause of disability worldwide (2), migraine has a 
profound socio-economic and personal impact. Migraine without aura (MWOA) is the most common 
form of migraine and is characterized by the recurrence of unilateral, severe headache attacks lasting 
4-72 hours with associated symptoms (3). In migraine with aura (MWA), migraine is preceded or 
accompanied by reversible focal neurological symptoms that last for less than 60 minutes (3). Recent 
findings suggest an association between migraine and obesity (4). This association could be mediated 
by adipokines, i.e. cytokines mainly secreted by adipose tissue, which participate in a number of 
processes that may play a role in migraine pathophysiology, such as inflammation and endothelial 
function (5). Among adipokines, the 16-kDa peptide hormone leptin leads to the reduction of food 
intake and increase of energy consumption through induction of anorexigenic factors. Importantly, 
leptin is able to act as a proinflammatory cytokine and modulate immune responses (6). Adiponectin 
is a 30-kDa protein involved in fatty acid oxidation and glucose synthesis (6, 7) and has been 
suggested to exert both pro- and antinflammatory properties (6). While leptin levels are usually 
increased in obesity (8), adiponectin levels have been shown to be reduced (9). Studies that assessed 
the levels of these two adipokines in subjects with migraine have provided conflicting results (5, 10-
17). One reason for the contradictory findings could be the heterogeneity of migraine. Indeed, the two 
subtypes MWOA and MWA could be differentially associated with adipokines. However, previous 
studies that assessed the association between adipokines and migraine have only partially taken into 
account these subtypes.  
Major depressive disorder (MDD), which has been frequently shown to be associated with both 
migraine and obesity, could also play a role in the association between migraine and obesity. Indeed, 
migraine patients have a 2-4 fold higher risk for MDD (18, 19) and several reviews and meta-analyses 
found depression to be associated with obesity (20-22). MDD could either be a condition predisposing 
to both migraine and obesity or a mediator of the association between the two conditions; i.e. if 
obesity predisposes to MDD, which predisposes to migraine, or the converse. 
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In the present study we aimed to assess the associations between serum leptin and adiponectin levels 
and migraine or migraine subtypes. Analyses were adjusted for a lifetime history of MDD in order to 
investigate the association between adipokines and migraine under consideration of depression status. 
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METHODS 
Subjects and cohort 
The data of the present paper stem from CoLaus|PsyCoLaus (23, 24), a cohort study designed to study 
mental disorders and cardiovascular risk factors (CVRFs)/cardiovascular diseases (CVD) in the 
general population. A total of 6,733 individuals (CoLaus), aged between 35 and 75 years, were 
randomly selected between 2003 and 2006 from the residents of the city of Lausanne (Switzerland) 
according to the civil register. In addition to anthropometric measures, DNA, serum and plasma 
samples were collected for the study of genetic variants and biomarkers associated with CVRFs (23). 
Subsequently, 67% of the participants of CoLaus in the age range of 35 to 66 years (N=5,535) agreed 
to take part in the psychiatric evaluation (PsyCoLaus), which resulted in a sample of 3,719 individuals 
who underwent both the somatic/cardiovascular and psychiatric exams (24). Ninety-two percent of 
these individuals were Caucasians. The gender distribution of the PsyCoLaus sample (47% men) did 
not differ significantly from that of the general population in the same age range (24). Although the 
youngest 5-year band of the cohort was underrepresented and the oldest 5-year band overrepresented, 
participants of PsyCoLaus [mean age 50.9; standard deviation (SD) 8.8 years] and individuals who 
refused to participate revealed comparable scores on the General Health Questionnaire (GHQ-12) 
(25), French translation (26), a self-rating instrument completed at the somatic exam.  
Of the initial 3,719 individuals, 656 were excluded because of missing adipokine levels, 30 because of 
missing migraine assessment, 6 because of missing lifetime MDD assessment, 1 because of missing 
blood glucose levels and 1 because of missing BMI, leaving a total of 3,025 subjects included in the 
present study. Excluded subjects were less frequently women (Chi-square = 24.8, < 0.001) and 
younger (Mann-Whitney U = 983,654, p = 0.012) than non-excluded ones. 
The CoLaus and PsyCoLaus studies were approved by the Institutional Ethic’s Committee of the 
University of Lausanne. Informed written consent was obtained from all participants. 
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Assessment of clinical and biological data 
The lifetime prevalence of migraine was assessed according to the criteria of the International 
Classification of Headache Disorders (ICHD-II) (3), using the validated French version of the Diagnostic 
Interview for Headache Syndromes (DIHS). Prevalence of MDD was assessed using the validated French 
translation (27) of the Diagnostic Interview for Genetic Studies (DIGS) (28). The French translation of 
the DIGS revealed excellent inter-rater reliability in terms of kappa and Yule's Y coefficients for major 
mood and psychotic disorders, whereas the 6-week test-retest reliability was slightly lower (29). 
Interviews were conducted by trained psychologists or psychiatrists and reviewed by an experienced 
senior psychologist. 
Body weight and height were assessed and a venous blood sample was obtained after an overnight fast 
(with a minimum fasting time equal to 8 hours). Samples were stored at -80°C and sent on dry ice to the 
laboratory. Total serum leptin levels were measured by Pathway Diagnostics (Los Angeles, CA) using 
enzyme linked immunosorbent assay (ELISA) [(American Laboratory Products Company, Windham, 
USA;  maximum inter-assay coefficient of variability (CV) = 12.8%; maximum intra-assay CV = 5.8%)]. 
Total serum adiponectin levels were measured using ELISA (R&D Systems, Inc, Minneapolis, USA; 
maximum inter-assay CV = 8.3%, maximum intra-assay CV = 8.3%). Fasting plasma glucose levels were 
measured by the Centre Hospitalier Universitaire Vaudois (CHUV) laboratory using a glucose 
dehydrogenase assay (Roche Diagnostics, CH; maximum inter-assay CV = 2.1%; maximum intra-assay 
CV = 1.0%).  
 
Statistical analysis 
Normal distribution of continuous variables was assessed using Kolmogorov-Smirnov test. Differences in 
continuous or categorical variables between subjects with migraine and controls were assessed using 
Mann-Whitney or Pearson Chi-Square tests, respectively. Correlations between adipokine levels and 
continuous variables were analyzed using Spearman correlation. The association of adipokine levels and 
diagnosis of migraine was assessed using binary logistic regression analysis. Three models of increasing 
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complexity were constructed. In model 1 the association was adjusted for age and sex; model 2 included 
adjustments applied in model 1 and was additionally adjusted for body mass index (BMI). Model 3 was 
same as model 2 and also adjusted for fasting plasma glucose levels, lifetime MDD and regular intake of 
antidepressants. In all these models, the dependent variable was the presence of migraine. In subsequent 
analysis based on migraine subtypes, the dependent variable was the presence of MWA or the presence of 
MWOA.  
In order to assess if sex or a lifetime history of MDD exerted an impact on the association between 
adipokine levels and migraine, models were first tested for potential interactions between adipokine 
levels, sex and lifetime diagnosis of MDD with respect to migraine and migraine subtypes. Specifically, 
the following interactions terms were included in the model: “sex x leptin levels”, “sex x adiponectin 
levels”, “MDD x leptin levels” and “MDD x adiponectin levels”. In the final model interaction terms that 
did not reach the level of statistical significance were removed. 
A p-value < 0.05 was considered significant. Statistical analyses were performed using SPSS v. 21 (IBM, 
Armonk, NY, USA). 
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RESULTS 
Demographic and clinical characteristics of the sample 
Demographic and clinical characteristics of the sample are shown in Table 1.Within the sample of 3,025 
participants 472 subjects (15.6%) met the lifetime diagnostic criteria for migraine. Among them 35% 
fulfilled also the criteria for MWA. All subjects except one had a diagnosis of episodic migraine 
according to ICHD-II criteria. Subjects with migraine were more likely to be younger and female, to have 
a lower BMI and lower fasting glucose levels, but higher leptin levels than controls (Table 1). 
Furthermore, individuals with migraine displayed more frequently a lifetime history of MDD and reported 
more frequently a regular intake of antidepressants.  
 
Adipokine levels and the prevalence of migraine and MWA 
Leptin levels were higher in women (mean = 16.2 ng/mL, SD = 11.4) than men (mean = 8.2 ng/mL, SD = 
7.2, p < 0.001), and were positively correlated with age (rho = 0.14), and BMI (rho = 0.38, p < 0.001 for 
both variables). Similarly, adiponectin levels were higher in women (mean = 12.3 g/mL, SD = 9.4) than 
men (mean = 7.2 g/mL, SD = 5.7, p < 0.001), correlated positively with age (rho = 0.13) and inversely 
with BMI (rho = -0.29, p < 0.001 for both variables). Before adjustments leptin levels were significantly 
higher in subjects with migraine than controls regardless of the migraine subtype (Table 1). In contrast 
there was no association between adiponectin levels and migraine or its subtypes. 
In order to test the impact of sex or comorbidity with MDD on the association between adipokine levels 
and migraine, a binary logistic regression model with interaction terms for sex and lifetime history of 
MDD was applied in a first step. We found no significant interactions between sex or lifetime MDD and 
adipokine levels regarding the risk for migraine, MWA or MWOA (Supplementary Table 1). Therefore, 
all interactions terms were removed from the model.   
Table 2 provides the results of the binary logistic regression analyses adjusting for sex and age (Model 1), 
Model 1 + BMI (Model 2) and Model 2 + fasting plasma glucose levels, lifetime MDD and regular intake 
of antidepressants (Model 3). In model 2 and model 3 higher leptin levels were still significantly 
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associated with an elevated lifetime prevalence of migraine and the MWA subtype but not with the 
MWOA subtype. The associations with leptin significantly differed between the two migraine subtypes 
evidenced by the established odds ratios for each subtype which lay beyond the 95% confidence interval 
of the other subtype. These models also revealed the absence of significant associations between 
adiponectin and migraine or migraine subtypes.  
Among the covariates included in the models female sex was associated with migraine and the MWOA 
subtype. Moreover, increasing age was associated with a reduced prevalence of migraine and the MWOA 
subtype and increasing BMI with a reduced prevalence of the MWA subtype. Finally, the lifetime history 
of MDD and migraine and its subtypes were strongly associated. 
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DISCUSSION 
In the current study we evaluated the association between adipokine levels and diagnosis of migraine in a 
large population sample including 3,025 participants from the CoLaus (23) and PsyCoLaus (24) studies. 
The major finding was the strong association between high leptin levels and migraine after adjustment for 
a comprehensive series of variables known to influence leptin levels, including demographic 
characteristics, BMI, and fasting glucose levels. Although a lifetime history of MDD was strongly 
associated with migraine and its two subtypes, the association between migraine and leptin levels was not 
explained by depression status. 
Previous studies that explored the relationship between leptin levels and migraine yielded inconsistent 
results. Given our evidence of differential associations between leptin levels and migraine subtypes the 
conflicting results of previous research could be due to variance of subtypes across studies. One study 
found lower leptin levels in 61 patients with episodic migraine compared with 64 healthy subjects before 
adjusting for fat mass (11), whereas another study documented higher crude but not adjusted leptin levels 
in 44 non-obese female migraine patients (13 of them with symptoms of aura) compared with 40 female 
controls (12). Another study assessing migraine subtypes reported negative results in a sample of 72 
patients with migraine, 59 with the diagnosis of probable migraine and 850 controls (14). However, only 
23 patients with migraine and 12 with probable migraine had a history of aura, which consisted in having 
experienced a visual aura in the past, rather than having met the MWA criteria according to ICHD-II.  
Interestingly, an association between leptin levels and migraine was in our study specifically seen for 
subjects with MWA. This finding is well in line with preclinical study results showing that 
hyperleptinemia has the potential to increase cortex susceptibility to cortical spreading depression (CSD), 
a mechanism that is suggested to induce auras during migraine attacks. CSD is characterized by a slowly 
propagating neuronal and glia depolarization wave followed by hyperpolarization (30). Chronic 
hyperleptinemia has been recently found to increase CSD in a rat model after intraperitoneal leptin 
administration (31) and Zucker fatty (ZF) rats (a model for obesity with intrinsic hyperleptinemia) display 
a significant higher frequency of KCl induced CSDs than Zucker lean (ZL) rats (31).  
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Mechanistically, it cannot be excluded that higher levels of leptin in patients with MWA may also be a 
feedback response to prolonged stress and hypothalamic–pituitary–adrenal (HPA) axis activation. 
Interestingly, in food depraved mice, leptin administration was shown to prevent the induction of 
corticotropin-releasing hormone (CRH) production in the paraventricular nucleus and to lower 
corticosterone levels (32). Moreover, in vivo photostimulation of orexin neurons in the lateral 
hypothalamic area was shown to induce a stress response through regulation of CRH secretion. Leptin 
administration inhibited orexin neuron activation through leptin receptor b-expressing inhibitory neurons, 
in this way suppressing the HPA axis (33).  
Our finding of a lack of association between migraine and adiponectine levels is in line with results of a 
meta-analysis (13) and one recent study (16) and contrasts with one study which revealed higher 
adiponectin levels in 68 migraine patients than 65 controls, independently of psychiatric comorbidities, 
migraine impact and allodynia (15). Another study documented an association only in men older than 50 
years but not in women with migraine (14).  
Our results need to be interpreted in the light of several limitations. First, participation rate was relatively 
low, which was probably due to the comprehensive physical and psychiatric assessments. 2) The cross-
sectional nature of the data reported herein did not allow us to determine the temporal sequence between 
adipokine level increases and the onset of migraine. 3) Total adiponectin but not high and low molecular 
weight oligomers were measured and assessed for association with migraine. These oligomers could be 
differentially associated with migraine (10). 4) All subjects except one had a diagnosis of episodic 
migraine. Therefore, we were not able to specifically evaluate if chronic migraine was associated with 
higher adiponectin levels as suggested by a previous study (10). In conclusion, the present study suggests 
that high leptin levels are associated with the risk of migraine and MWA. Prospective studies which can 
provide clues to the temporal sequence between leptin levels increase and the onset of migraine are 
needed to confirm our findings and to further elucidate the role of leptin in migraine pathogenesis. Future 
studies should also subtype into high and low molecular weight oligomers in order to unravel potential 
differential effects of these specific oligomers on the risk of migraine. 
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Table 1. Demographic and clinical characteristics of the sample (n = 3,025) 
  Controls Migraine  Migraine vs. controls MWA MWA vs. controls MWOA MWOA vs. controls 
N 2,553 472 - 165 - 307 - 
Age (years) 50.4 (± 8.9) 48.8 (± 8.5) < 0.001 49.4 (± 8.8) 0.10 48.4 (± 8.3) < 0.001 
Gender female, n (%) 1,326 (52%) 335 (71%) < 0.001 99 (60%) 0.044 236 (76.9%) < 0.001 
BMI (Kg/m
2
) 25.6 (± 4.3) 25.1 (± 4.3) 0.01 25.2 (± 4.2) 0.20 25.1 (± 4.3) 0.018 
Glucose (mmol/L) 5.5 (± 1.1) 5.4 (± 0.8) 0.001 5.4 (± 0.8) 0.42 5.3 (± 0.7) < 0.001 
Lifetime MDD, n (%) 1,027 (40%) 274 (58%) < 0.001 101 (61.2%) < 0.001 173 (56.4%) < 0.001 
Regular intake of antidepressants, n (%) 191 (7%) 68 (14%) < 0.001 23 (13.9%) 0.003 45 (14.7%) < 0.001 
Leptin (ng/mL) 12.2 (± 10.4) 14.6 (± 11) < 0.001 14.2 (± 10.8) 0.013 14.8 (± 11.2) < 0.001 
Adiponectin (g/mL) 10.0 (± 8.4) 10.1 (± 7.9) 0.15 9.3 (± 5.2) 0.83 10.5 (± 9.0) 0.09 
        BMI, body mass index; MDD, major depressive disorder; MWA, migraine with aura; MWOA, migraine without aura  
Continuous variables are expressed as mean ± standard deviation; p-values are calculated using Mann-Whitney test or Pearson chi square test, comparing subjects with migraine 
or migraine subtypes vs. controls. Significant differences are indicated in bold. 
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Table 2. Association between adipokine levels and diagnosis of migraine and migraine subtypes according to logistic regression models 
  Migraine (N = 472) MWA (n = 165) MWOA (N = 307) 
 Vs. controls (N = 2,553) 
  Adj OR (95% CI) P-value Adj OR (95% CI)  P-value Adj OR (95% CI) P-value 
Model 1 
      Leptin 1.11 (1.01-1.23) 0.041 1.15 (0.99-1.34) 0.078 1.08 (0.96-1.22) 0.195 
Adiponectin 0.92 (0.82-1.03) 0.166 0.94 (0.70-1.10) 0.192 0.94 (0.83-1.08) 0.398 
Sex female 2.22 (1.75-2.83) < 0.001 1.36 (0.94-1.96) 0.106 3.05 (2.25-4.14) < 0.001 
Age 0.98 (0.97-0.99) < 0.001 0.99 (0.97-1.00) 0.130 0.97 (0.96-0.99) < 0.001 
Model 2 
      
Leptin 1.18 (1.04-1.35) 0.011 1.34 (1.10-1.63) 0.004 1.10 (0.94-1.28) 0.270 
Adiponectin 0.91 (0.81-1.03) 0.121 0.84 (0.67-1.05) 0.118 0.94 (0.83-1.08) 0.388 
Sex female 2.02 (1.55-2.65) < 0.001 1.08 (0.72-1.63) 0.701 3.00 (2.13-4.21) < 0.001 
Age 0.98 (0.97-0.99) < 0.001 0.99 (0.97-1.01) 0.237 0.97 (0.96-0.99) < 0.001 
BMI 0.98 (0.95-1.01) 0.133 0.94 (0.90-0.99) 0.022 1.00 (0.96-1.03) 0.831 
Model 3 
      
Leptin 1.17 (1.03-1.34) 0.018 1.34 (1.10-1.63) 0.004 1.09 (0.92-1.02) 0.328 
Adiponectin 0.91 (0.81-1.03) 0.106 0.83 (0.66-1.03) 0.098 0.94 (0.83-1.08) 0.371 
Sex female 1.77 (1.35-2.33) < 0.001 0.89 (0.58-1.36) 0.593 2.70 (1.91-3.81) < 0.001 
Age 0.98 (0.97-0.99) 0.001 0.99 (0.97-1.01) 0.375 0.97 (0.96-0.99) < 0.001 
BMI 0.98 (0.94-1.01) 0.126 0.94 (0.89-0.99) 0.018 0.99 (0.96-1.03) 0.795 
Glucose 0.98 (0.88-1.10) 0.780 0.99 (0.83-1.18) 0.896 0.98 (0.85-1.13) 0.779 
Lifetime MDD 1.63 (1.32-2.01) < 0.001 2.13 (1.52-2.99) < 0.001 1.40 (1.09-1.8) 0.009 
Regular intake of antidepressants 1.69 (1.24-2.30) 0.001 1.62 (1.00-2.61) 0.050 1.77 (1.22-2.55) 0.002 
Adj, adjusted; BMI, body mass index; CI, confidence interval; MDD, major depressive disorder; MWA, migraine with aura; MWOA, 
migraine without aura; OR, odds ratio. In Model 1 adipokine levels are adjusted for age and sex; in model 2 adipokine levels are adjusted for 
variables included in Model 1 + BMI; in Model 3 adipokine levels are adjusted for variables included in Model 2 + fasting glucose levels, 
lifetime history of MDD and regular intake of antidepressants. Significant results are reported in bold. 
OR with 95% CI are calculated in relationship to the increase of 1 unit of standard deviation in leptin or adiponectin levels 
 
